Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMK0UOY)

Drug Name
ME-401 Drug Info
Synonyms
Zandelisib; UNII-8Z28M5SX0X; 8Z28M5SX0X; 4-yl)-1,3,5-triazin-2-amine; 1401436-95-0; [2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl}-6-(morpholin-; 4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-N-{2-methyl-1-; Zandelisib [INN]; Zandelisib [USAN]; SCHEMBL12936730; GTPL10627; ACC-524; PWT-143; ME401; PW-143; WHO 11202; ZINC148868634; Example 51 [WO2012135160A1]; HY-109198; CS-0119144; A35 [WO2012135160A1]; 1,3,5-Triazin-2-amine, 4-(2-(difluoromethyl)-1H-benzimidazol-1-yl)-N-(1,1-dimethyl-2-(2-(1-methyl-4-piperidinyl)phenyl)ethyl)-6-(4-morpholinyl)-; 4-(2-(Difluoromethyl)benzimidazol-1-yl)-N-(1,1-dimethyl-2-(2-(1-methyl-4-piperidyl)phenyl)ethyl)-6-morpholino-1,3,5-triazin-2-amine; 4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine
Indication
Disease Entry ICD 11 Status REF
Follicular lymphoma 2A80 Phase 2 [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 1 [2]
Diffuse large B-cell lymphoma 2A81 Phase 1 [2]
Lymphoma 2A80-2A86 Phase 1 [2]
Cross-matching ID
PubChem CID
66571003
CAS Number
CAS 1401436-95-0
TTD Drug ID
DMK0UOY

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PI3-kinase delta (PIK3CD) TTGBPJE PK3CD_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
PI3-kinase delta (PIK3CD) DTT PIK3CD 5.711 5.814 6.011 6.508
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Follicular lymphoma
ICD Disease Classification 2A80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
PI3-kinase delta (PIK3CD) DTT PIK3CD 4.31E-16 -0.37 -0.91
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03768505) Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)